Search Results

June 4, 2017

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

June 1, 2017

Janssen Announces Submissions in Europe and US for Single- Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment

- Two-drug regimen could offer many patients the option to switch to a regimen that does not include a nucleotide reverse transcriptase inhibitor -

Innovative Medicine

May 30, 2017

Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. For The Oral Interlukin-23 Receptor Antagonist Drug Candidate For The Treatment of Inflammatory Bowel Disease

Long-standing relationship between Johnson & Johnson Innovation, Janssen and Protagonist Therapeutics leads to advancement of promising oral drug candidate for Crohn’s disease and ulcerative colitis

Innovative Medicine

May 17, 2017

ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib

Innovative Medicine

May 5, 2017

Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists

Patients Taking INVOKANA® 300 mg Were Significantly Less Likely to Discontinue the Medication or Be Prescribed a New Antihyperglycemic Agent

Innovative Medicine

April 28, 2017

Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups

Filing seeks update to prescribing information to include additional dosage of XARELTO® to reduce risk of recurrent VTE

Innovative Medicine

April 28, 2017

European Commission Extends Approval for Janssen’s DARZALEX®▼(daratumumab) to Include Multiple Myeloma Patients Who Have Received at Least One Prior Therapy

First-in-class CD38-directed monoclonal antibody now approved for use in combination with two standard of care regimens

Innovative Medicine

April 4, 2017

Health Risk Assessments Shed Light on Early Predictors of Depression

Innovative Medicine

April 4, 2017

U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

Innovative Medicine

April 3, 2017

Janssen Collaborates with Premier Inc. on Unique Study to Improve Stroke Risk Management among Hospitalized Patients with Atrial Fibrillation

The QUANTUM AF study will evaluate the impact of a hospital quality improvement program on the use of new guidelines to treat patients with atrial fibrillation (AF) at risk for ischemic stroke

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine